ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Kao shares rise on coronavirus antibody findings

Joint research with startup and Kitasato University opens door to new treatments

 Kao joins a number of other Japanese companies in the race to find a potential treatment for the deadly virus.

TOKYO -- Shares of Japanese household goods maker Kao rose on Thursday after the company said it has jointly developed an antibody that suppresses new coronavirus infections.

The VHH antibody developed by the partnership is derived from camelids that are one-tenth the size of conventional antibodies and less costly to produce.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more